

Supplemental Digital Content 1

Table 1. Monitoring frequency per parameter per evaluated time interval

	Monitoring interval						
Parameter, n (%)	0-3 mos. (n=366)	3-6 mos. (n=334)	6-12 mos. (n=287)	12-18 mos. (n=259)	18-24 mos. (n=245)	24-30 mos. (n=224)	30-36 mos. (n=212)
Treatment response	294 (80.3)	206 (61.7)	203 (70.7)	186 (71.8)	156 (63.7)	132 (58.9)	123 (58.0)
Extrapyramidal side effects	32 (8.7)	21 (6.3)	27 (9.4)	19 (7.3)	9 (3.7)	11 (4.9)	11 (5.2)
Prolactin related side effects	0 (0.0)	2 (0.6)	3 (1.0)	3 (1.2)	3 (1.2)	1 (0.4)	3 (1.4)
Other side effects	245 (66.9)	142 (42.5)	146 (50.9)	128 (49.4)	98 (40.0)	84 (37.5)	83 (39.2)
	0-3 mos. prior to start (n=426)	2-6 wks. (n=397)	6-10 wks. (n=379)	10-14 wks. (n=364)	Annually (<395 days between occurrences) (n=280)		
Height	196 (46.0)	60 (14.1)	47 (12.4)	40 (11.0)	119 (42.5)		
Weight	224 (52.6)	82 (19.2)	63 (16.6)	54 (14.8)	129 (46.1)		
Blood pressure	163 (38.3)	-	-	37 (10.2)	58 (20.7)		
Pulse	94 (22.1)	-	-	23 (6.3)	39 (13.9)		
Waist circumference	1 (0.2)	-	-	-	0		
Glucose levels	13 (3.1)	-	-	3 (0.8)	3 (1.1)		
Lipid profile	11 (2.6)	-	-	2 (0.5)	2 (0.7)		
Discussion of continued need	-	-	-	-	12 (4.3)		

Abbreviations: mos., months; wks., weeks